Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 YearsGlobeNewsWire • 11/05/21
Ocugen to Host Conference Call on Tuesday, November 9 at 8:30 a.m. ET to Discuss Third Quarter 2021 Financial Results and Provide Business UpdateGlobeNewsWire • 11/02/21
3 Hypergrowth Stocks Expected to Increase Sales 21,551% to 948,737% by 2023The Motley Fool • 10/28/21
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)GlobeNewsWire • 10/27/21
Ocugen Reverses Course From Monday's Massive Surge As COVID-19 Vaccine Partner Faces WHO SetbackBenzinga • 10/27/21